PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11451200-6 2001 Annexin V-flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling assay showed that TNF-alpha can induce apoptosis in cells treated with CDDP. Cisplatin 170-174 annexin A5 Homo sapiens 0-9 33773191-5 2021 METHODS: The efficacy of DS-1 alone or in combination with cisplatin in lung cancer cells was determined by MTT, nuclear staining, and annexin V/PI assay. Cisplatin 59-68 annexin A5 Homo sapiens 135-144 33203600-8 2021 MTT and annexin V/propidium iodide dual staining results demonstrated that co-loading of CDDP and PTX into PSPm had a synergistic effect in killing lung cancer cells and exerted superior antitumor activity over the combination of single drug-loaded PSPm or the combination of free-CDDP and free-PTX at equivalent drug amounts. Cisplatin 89-93 annexin A5 Homo sapiens 8-17 35624790-4 2022 Cisplatin/SK2 triggered also more apoptosis inductions in terms of subG1 accumulation, annexin V, pancaspase, and caspase 3/8/9 measurements. Cisplatin 0-9 annexin A5 Homo sapiens 87-96 35636434-6 2022 Furthermore, analysis of Annexin V/FITC assay data revealed that the rate of apoptosis in MG63 OS cell line remarkably promoted after treated with cisplatin and melatonin combination. Cisplatin 147-156 annexin A5 Homo sapiens 25-34 33178272-9 2020 Annexin V/PI staining showed that Rab11a overexpression suppressed cisplatin-induced apoptosis, while Rab11a depletion promoted cell apoptosis. Cisplatin 67-76 annexin A5 Homo sapiens 0-9 33120322-6 2020 Further Annexin V-FITC/propidium iodide dual staining assay provided evidence that 10 and 12 induced apoptosis via different pattern to cisplatin and their combination with cisplatin promoted more cells to enter late apoptosis and necrosis. Cisplatin 173-182 annexin A5 Homo sapiens 8-17 33101710-10 2020 Moreover, SEMGs (especially SEMG1) strongly increased the number of Annexin V-positive apoptotic cells manifesting an increased sensitivity to genotoxic drugs including doxorubicin, etoposide, and cisplatin. Cisplatin 197-206 annexin A5 Homo sapiens 68-77 33344139-6 2020 In particular, Q-annexin V shows superior utility for in vivo apoptosis fluorescence imaging in animal models of cisplatin-induced acute kidney injury and cancer immune therapy, compared to the conventional polarity-sensitive pSIVA-IANBD or annexin V-Alexa647 conjugates. Cisplatin 113-122 annexin A5 Homo sapiens 17-26 33066414-10 2020 Annexin V-FITC apoptosis kit showed a higher apoptotic effect induced by a Schiff base complex compared to the cisplatin-treated group. Cisplatin 111-120 annexin A5 Homo sapiens 0-9 33085742-6 2020 Meanwhile, BIX plus cis-platinum (Cis) treatment induced pyroptosis in NPC cells as featured by cell swelling and bubble blowing from the plasma membrane, the increased frequency of annexin V and propidium iodide (PI) double-positive cells, as well as the cleavage of gasdermin E (GSDME) and caspase-3. Cisplatin 20-32 annexin A5 Homo sapiens 182-191 32420069-6 2020 Methods: In lung adenocarcinoma (AD) cells, protein expression of LATS1 and LATS2 were determined by western blotting; cell viability and apoptosis were measured by MTT and annexin V staining after treatment with cisplatin; subcellular distributions of LATS proteins were determined by immunofluorescence microscopy; LATS2 expression was modulated by shRNA-mediated knockdown or ectopic expression in cancer cell lines. Cisplatin 213-222 annexin A5 Homo sapiens 173-182 32210629-10 2020 Annexin V/PI staining and MTT assay results demonstrated that melatonin assisted cisplatin-induced apoptosis accompanied with upregulated caspase-3 and poly ADP-ribose polymerase (PARP) cleavage, as well as Bcl-2 expression. Cisplatin 81-90 annexin A5 Homo sapiens 0-9 31638228-6 2019 Moreover, it was shown that ACSS2 inhibition by siRNA not only greatly interfered with proliferation under NS but also participated in DNA repair after cisplatin treatment via PCNA suppression, and the acceleration of cell death was dependent on the activation of the AMPK pathway as revealed by the Annexin V/PI and TUNEL assay results. Cisplatin 152-161 annexin A5 Homo sapiens 300-309 31512406-6 2020 Apoptosis-inducing effect of sanguinarine alone and in combination with cisplatin was evaluated by annexin V/PI assay and DAPI staining. Cisplatin 72-81 annexin A5 Homo sapiens 99-108 30896871-6 2019 When DCs and DC-Tregs were co-cultured with cisplatin-resistant A549 cells, the proportion of apoptosis in the co-culture groups was increased under treatment with cisplatin, which was detected by Annexin V/propidium Iodide staining and western blotting. Cisplatin 44-53 annexin A5 Homo sapiens 197-206 31239661-9 2019 Annexin V-FITC/PI assay and cell cycle analysis confirmed that CDDP and OA synergistically promoted greater HepG2 cells apoptosis for the CDDP/OA-LCC NPs as compared to their individual free drug solutions and NPs-treated groups. Cisplatin 63-67 annexin A5 Homo sapiens 0-9 31239661-9 2019 Annexin V-FITC/PI assay and cell cycle analysis confirmed that CDDP and OA synergistically promoted greater HepG2 cells apoptosis for the CDDP/OA-LCC NPs as compared to their individual free drug solutions and NPs-treated groups. Cisplatin 138-142 annexin A5 Homo sapiens 0-9 30896871-6 2019 When DCs and DC-Tregs were co-cultured with cisplatin-resistant A549 cells, the proportion of apoptosis in the co-culture groups was increased under treatment with cisplatin, which was detected by Annexin V/propidium Iodide staining and western blotting. Cisplatin 164-173 annexin A5 Homo sapiens 197-206 29113360-6 2017 Cell viability and Annexin V/PI staining showed that miR-488 downregulated cell survival and increased apoptosis rate when treated with cisplatin and paclitaxel. Cisplatin 136-145 annexin A5 Homo sapiens 19-28 30483332-5 2018 Moreover, the apoptogenic activity of cisplatin and NaN3 was studied using flow cytometry (Annexin V/PI double staining) and scanning electron microscopy (SEM). Cisplatin 38-47 annexin A5 Homo sapiens 91-100 31179330-6 2019 Meanwhile, the apoptosis of cells induced by cisplatin or paclitaxel was assessed by Annexin-V/propidium iodide staining analysis. Cisplatin 45-54 annexin A5 Homo sapiens 85-94 30690121-6 2019 RESULTS: Cisplatin causes dose- and time-dependent increase of H2O2 level in TMRE-positive and PE Annexin V-negative cancer cells. Cisplatin 9-18 annexin A5 Homo sapiens 98-107 29534504-7 2018 The percentage of Annexin V-positive cells also increased following cisplatin treatment. Cisplatin 68-77 annexin A5 Homo sapiens 18-27 28053903-8 2016 The proportion of annexin V-FITC-stained cells increased following treatment with cisplatin. Cisplatin 82-91 annexin A5 Homo sapiens 18-27 29088864-9 2017 Cell viability and Annexin V/PI staining demonstrated that Rab27A maintained cancer cell survival and reduced apoptosis rate when treated with cisplatin. Cisplatin 143-152 annexin A5 Homo sapiens 19-28 29979530-7 2017 The sensitivity of cisplatin administration after transfecting GGI/MDR1 siRNA polyplexs was performed with MTT and Annexin V-FITC/PI methods. Cisplatin 19-28 annexin A5 Homo sapiens 115-124 28721072-4 2017 METHODS: CXCL12 blocks cisplatin-induced apoptosis in A549, and the results were shown by propidium iodide/annexin V staining in vitro. Cisplatin 23-32 annexin A5 Homo sapiens 107-116 27591926-3 2016 The combination treatment of cisplatin and resveratrol (CDDP/RSV) synergistically induced apoptosis, as evidenced by typical cell morphological changes, the appearance of sub-G0/G1 peak, an increase in the Annexin V(+) cells and the cleavage of caspase-3 and PARP. Cisplatin 29-38 annexin A5 Homo sapiens 206-215 27591926-3 2016 The combination treatment of cisplatin and resveratrol (CDDP/RSV) synergistically induced apoptosis, as evidenced by typical cell morphological changes, the appearance of sub-G0/G1 peak, an increase in the Annexin V(+) cells and the cleavage of caspase-3 and PARP. Cisplatin 56-60 annexin A5 Homo sapiens 206-215 26531156-4 2016 Cisplatin-induced apoptosis after transfection was measured by flow cytometry using Annexin V/propidium iodide (PI) double staining. Cisplatin 0-9 annexin A5 Homo sapiens 84-93 27165250-8 2016 Regarding annexin V/propidium results, treatment of MCF-7 cells with LD50 concentrations of cisplatin and Mg showed 59% and 44% apoptosis at 24h, respectively. Cisplatin 92-101 annexin A5 Homo sapiens 10-19 26575528-11 2016 Annexin V-FITC staining revealed that cisplatin and HDACIs combinations induced more apoptotic cell death of both KKU-100 and KKU-M214 cells than the single drug. Cisplatin 38-47 annexin A5 Homo sapiens 0-9 27446473-3 2016 The sensitivity of laryngeal cancer cells to multiple drugs and cisplatin-induced apoptosis was determined by CCK-8 assay and Annexin-V/propidium iodide staining analysis, respectively. Cisplatin 64-73 annexin A5 Homo sapiens 126-135 27522712-4 2016 MMSCs viability after incubation with cisplatin was detected by the number of apoptotic and necrotic cells using ANNEXIN V-FITC--PI Kit (Immunotech, France). Cisplatin 38-47 annexin A5 Homo sapiens 113-122 26770460-5 2015 Flow cytometry was used to analyze apoptosis induced by cisplatin with Annexin V/PI double staining technique. Cisplatin 56-65 annexin A5 Homo sapiens 71-80 24669930-6 2014 Co-delivery of cisplatin and siRNAs with NMOFs led to an order of magnitude enhancement in chemotherapeutic efficacy in vitro, as indicated by cell viability assay, DNA laddering, and Annexin V staining. Cisplatin 15-24 annexin A5 Homo sapiens 184-193 25625867-5 2015 Annexin V-fluorescein isothiocyanate/propidium iodide dual labeling analyses demonstrated a significant increase in the apoptotic rate of Du145 cells following transfection of Pcdc5 in combination with cisplatin treatment. Cisplatin 202-211 annexin A5 Homo sapiens 0-9 25547433-6 2015 The effect of the ectopic expression of RKIP on the cisplatin-induced apoptosis of gastric cancer cell was detected using flow cytometry after having been double stained with Annexin V/PI. Cisplatin 52-61 annexin A5 Homo sapiens 175-184 25152024-4 2014 Cisplatin-induced apoptosis was detected using Annexin V/PI staining and flow cytometry, as well as MTS analyses. Cisplatin 0-9 annexin A5 Homo sapiens 47-56 26537082-3 2015 Annexin V-FITC assay was used to quantify the extent of apoptosis in chrysin and chrysin+cisplatin treated cells. Cisplatin 89-98 annexin A5 Homo sapiens 0-9 26458859-5 2015 The effect of miR-26a on cisplatin-induced apoptosis were determined by Annexin V/propidium iodide (PI) double staining method and flow cytometry. Cisplatin 25-34 annexin A5 Homo sapiens 72-81 25663887-8 2015 Annexin V-fluorescein isothiocyanate/propidium iodide staining followed by flow cytometric analysis confirmed that cisplatin was able to induce apoptosis in tumor cells. Cisplatin 115-124 annexin A5 Homo sapiens 0-9 25367849-4 2014 Primary CRC cells were separated from cancer tissues, and its viability or apoptosis after treatment with DDP was determined with MTT or Annexin V/PI assays, respectively. Cisplatin 106-109 annexin A5 Homo sapiens 137-146 24318879-0 2014 Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis. Cisplatin 22-31 annexin A5 Homo sapiens 8-18 24675768-9 2014 In addition, pretreatment of cisplatin-resistant HNSCC cell lines with H-4073 significantly reversed the chemo-resistance as observed by cell viability assay (MTT), apoptosis assay (Annexin V binding) and cleaved caspase-3 (Western blot). Cisplatin 29-38 annexin A5 Homo sapiens 182-191 24068565-5 2014 The effects of miR-34a ectopic expression on apoptosis of cisplatin-induce gastric cancer cell were determined by Annexin V/propidium iodide (PI) double staining method and flow cytometry. Cisplatin 58-67 annexin A5 Homo sapiens 114-123 24318879-4 2014 Real-time PCR and Western blot analysis, together with immunofluorescence analysis, showed that the expression of annexin A5 significantly increased in the presence of cisplatin in both human and rat renal epithelial cells. Cisplatin 168-177 annexin A5 Homo sapiens 114-124 24318879-7 2014 Moreover, cisplatin strongly induced translocation of annexin A5 into mitochondria. Cisplatin 10-19 annexin A5 Homo sapiens 54-64 24318879-12 2014 Taken together, our data suggest that annexin A5 may play a crucial role in cisplatin-induced toxicity by mediating the mitochondrial apoptotic pathway via the induction and oligomerization of VDAC. Cisplatin 76-85 annexin A5 Homo sapiens 38-48 24369240-6 2013 The effect of CK8 down-regulation on cell apoptosis induced by cisplatin was detected with Annexin V/PI staining. Cisplatin 63-72 annexin A5 Homo sapiens 91-100 22137560-7 2012 Cisplatin-induced apoptosis in NSCLC cells was evaluated by flow cytometry after Annexin V staining. Cisplatin 0-9 annexin A5 Homo sapiens 81-90 23741487-6 2013 The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. Cisplatin 33-42 annexin A5 Homo sapiens 81-90 23319321-6 2013 Moreover, knockdown of ADAM8 caused a significant increase in cisplatin-induced apoptosis assessed by annexin-V/propidium iodide double staining, accompanying with enhanced cleavage of caspase-3 and poly(ADP-ribose) polymerase. Cisplatin 62-71 annexin A5 Homo sapiens 102-111 23973653-4 2013 The sensitivity to cisplatin of gastric cancer cells with/without PPZ pretreatment was assessed by IC50 calculation and Annexin V/PI assay. Cisplatin 19-28 annexin A5 Homo sapiens 120-129 24265863-0 2013 Annexin a5 as a new potential biomarker for Cisplatin-induced toxicity in human kidney epithelial cells. Cisplatin 44-53 annexin A5 Homo sapiens 0-10 24265863-5 2013 Treatment with cisplatin on HK-2 cells caused the increase of annexin A5 expression in protein and mRNA levels. Cisplatin 15-24 annexin A5 Homo sapiens 62-72 24265863-7 2013 Taken together, these results suggest the possibility of annexin A5 as a new biomarker for cisplatin-mediated nephrotoxicity. Cisplatin 91-100 annexin A5 Homo sapiens 57-67 24033949-7 2013 Cell apoptosis and survival with half-maximum inhibitory concentration (IC50) of cisplatin were determined by Annexin V-FITC/PI and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), respectively. Cisplatin 81-90 annexin A5 Homo sapiens 110-119 22359193-5 2012 The effects of cisplatin in combination with PDCD5 on the proliferation and apoptosis were measured by MTT, Annexin-V-FITC/PI dual labeling and cell cycle analysis, respectively. Cisplatin 15-24 annexin A5 Homo sapiens 108-117 20869960-3 2010 The effects of cisplatin in combination with PDCD5 on the proliferation and apoptosis of colorectal cancer cells were measured by using MTT analysis, Hoechst 33258 analysis and flow cytometry with Annexin-V-FITC/PI dual labeling, respectively. Cisplatin 15-24 annexin A5 Homo sapiens 197-206 20429876-12 2010 Curcumin pre-treatment followed by exposure to low doses of cisplatin increased apoptosis as indicated by annexin V staining and cleavage of caspase 9 and PARP. Cisplatin 60-69 annexin A5 Homo sapiens 106-115 16109459-2 2005 Incubation of type I spiral ligament fibrocytes derived from gerbil cochlea with cisplatin induced dose- and time-dependent apoptosis as demonstrated by annexin V conjugated to fluorescein isothiocyanate/prodidium iodide assays. Cisplatin 81-90 annexin A5 Homo sapiens 153-162 15028782-8 2004 Cisplatin and staurosporine also induced annexin V staining in the human epithelial cancer cell lines Caki-1 (kidney carcinoma), A549 (lung carcinoma), A172 (glioblastoma), and murine lymphocytic leukemia L1210 cells. Cisplatin 0-9 annexin A5 Homo sapiens 41-50 15028782-9 2004 Pretreatment with ZVAD-fmk inhibited cisplatin-induced annexin V staining in Caki-1, A172, and A549 cells but had no affect in L1210 cells. Cisplatin 37-46 annexin A5 Homo sapiens 55-64 15161024-12 2004 While Cisplatin predominantly induces apoptosis documented by morphology, Annexin V staining and caspase 8 activation, the Ferrocene and Rhodium-Ferrocene complexes induce late necrosis and abnormal nuclear morphology. Cisplatin 6-15 annexin A5 Homo sapiens 74-83 20814891-8 2010 Cell apoptosis after cisplatin treatment was evaluated by Annexin V staining, which showed that MPE cancer cells with higher pStat1 changes after IFN-gamma stimulation were more resistant to cisplatin. Cisplatin 21-30 annexin A5 Homo sapiens 58-67 20952762-0 2010 Analysis of protein phosphorylation in cisplatin-treated human cells following annexin V-based separation and multi-antibody screening. Cisplatin 39-48 annexin A5 Homo sapiens 79-88 17909044-8 2007 Importantly, betaIII-siRNA cells displayed a significant dose-dependent increase in Annexin V staining when treated with either paclitaxel or cisplatin, compared with controls. Cisplatin 142-151 annexin A5 Homo sapiens 84-93 17508026-4 2007 The mitogen-activated protein kinase kinase (MEK) inhibitor (U0126) was able to block this effect and reduced cell viability and sensitized cells to cisplatin-induced apoptosis, as shown by PARP cleavage, caspase 3 expression, and annexin-V staining. Cisplatin 149-158 annexin A5 Homo sapiens 231-240 12919886-5 2003 Pretreatment with sub-toxic or slightly toxic concentrations of chemotherapeutic agents (cis-diammine dichloroplatinum, CDDP and doxorubicin, DXR) sensitized both cell lines to TRAIL-induced apoptosis, as assessed by the propidium iodide or Annexin V-Cy5 staining method. Cisplatin 89-118 annexin A5 Homo sapiens 241-250 11435891-6 2001 Cell death mediated by cisplatin and doxorubicin was characterized by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling analysis, Hoechst 33258 staining and annexin-V binding assay. Cisplatin 23-32 annexin A5 Homo sapiens 198-207 11435891-9 2001 Cisplatin induced cell death undergoes apoptosis, as demonstrated by Hoechst staining, annexin-V assay and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling, respectively. Cisplatin 0-9 annexin A5 Homo sapiens 87-96